Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus casei BL 2401
- Development stage
- Unknown
- Lead developer
- Special Hospital for Cerebral Palsy and Developmental Neurology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus casei BL 2401 is a specific probiotic bacterial strain being investigated for its therapeutic potential in neurodevelopmental disorders. As a component of a probiotic mixture, it is designed to modulate the microbiota-gut-brain axis by restoring intestinal microbial balance and strengthening the intestinal barrier. Mechanistically, the strain demonstrates the ability to adhere to the intestinal mucosa, inhibit the growth of pathogenic bacteria, and stimulate the secretion of the anti-inflammatory cytokine Interleukin-10 (IL-10). It is currently being evaluated in clinical trials for the treatment of behavioral and cognitive symptoms in children with Fragile X Syndrome (FXS). The strain is registered with the French National Collection of Cultures of Microorganisms (CNCM) and is considered safe under EFSA's Qualified Presumption of Safety (QPS) guidelines.
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on Lactobacillus casei BL 2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus casei BL 2401.